Back A A A Font Size Receive E-mail Alerts Press Releases

Experts from Pakistan Society of Interventional Cardiology Visits MicroPort®


Shanghai, China – On September 6, Professor Bashir Hanif, President of Pakistan Society of Interventional Cardiology, and Professor Amber Malik, General Secretary of the society, visited Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort®"). The visit took place after the Pakistani experts attended a signing ceremony for the Sino-Pakistan "Belt and Road Interventional Cardiology Training Program", which was co-hosted by Chinese Medical Doctor Association and China Cardiovascular Association during the 20th Scientific Annual Congress of Chinese Society of Cardiology & the 12th Qianjiang International Cardiovascular Conference.
During the visit, Professor Hanif and Professor Malik went to the MicroPort® Self-experience Center with introduction about the development history, business sectors and globalization of MicroPort®, gaining a better knowledge of the various product lines and innovative technologies of MicroPort®. They are also deeply impressed by the outstanding innovation capability and diversified development strategy of MicroPort®. Afterwards, they went to one of the production facilities of MicroPort®, and took a look at the manufacturing process of MicroPort® products.
Professor Hanif and Professor Malik also had positive exchanges and interactions with the MicroPort® employees. Professor Hanif said that the rich product lines and strong R&D capability of MicroPort® had left a deep impression on him, while the extremely fine manufacturing process and rigorous quality assurance system at the production facilities had also boosted his confidence in the high-end medical devices of MicroPort® and even China. He added that the cardiovascular diseases were the top fatal diseases in Pakistan, but lots of local patients suffering from the diseases lacked timely treatment with efficacy so far due to the shortages of catheter labs, various kinds of interventional devices and equipment, and the clinicians who had received cardiovascular interventional education and training in a systematic manner in Pakistan. He hoped for further cooperation with MicroPort® to introduce more high-end medical devices and services into Pakistan, so as to benefit more local patients.
In September 2016, the Firehawk Rapamycin Target Eluting Coronary Stent System ("Firehawk®") acquired the registration approval from Drug Regulatory Authority of Pakistan (DRAP) and officially entered the Pakistan market. As of end of 2017, approximately 4.5 million coronary stents manufactured by MicroPort®, including the Firehawk® stent, have been implanted in about 3.5 million patients worldwide. Firehawk® has now been approved for use and marketed in 36 countries and territories globally.
Pakistan is a major cooperation partner of China in the "Belt and Road Initiative" of China. In the future, MicroPort® will continue to adhere to its vision that the people are the most essential aspect of building a leading, globalized medical corporation, where the patient always comes first, in the area of high-technology therapies embodied by minimally invasive and other emerging medical technologies. MicroPort® will actively explore the international market on the basis of independent innovation, so as to benefit more patients globally with the high-end medical device products and services from China.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:Beflex Active Pacing Lead Family Approved in China
[Next]:MicroPort® Orthopedics Holds First University of Hong Kong - Shenzhen Hospital Total Knee Arthroplasty Technique (TKA) Advancement Course